When 42-year-old teacher Amina Rahman first started taking tirzepatide in early 2024, she didn’t just rely on the medication—she set a clear goal: lose 20% of her body weight within a year. Her determination wasn’t unique, but according to one of the largest real-world studies on the drug to date, it may have been pivotal. Analyzing data from over 80,000 adults across the U.S. and U.K., researchers found that behavioral choices like setting weight goals were among the strongest predictors of success on tirzepatide, a GLP-1 medication marketed as Mounjaro and Zepbound. The study, conducted by London-based digital health service Voy (Menwell Ltd.) and the Predictive Medicine Group at Boston Children’s Hospital and Harvard Medical School, offers new insight into why weight loss outcomes vary so widely—even when patients are on the same powerful medication.
Why does this matter? As GLP-1 drugs reshape the landscape of obesity treatment, understanding what drives their effectiveness is critical. These medications are not magic bullets, and this study underscores that human behavior plays a central role. Women in the study lost more weight on average than men, and those without pre-existing conditions like type 2 diabetes, high blood pressure, or obstructive sleep apnea saw better results. But even more telling was the impact of mindset: participants who had previously attempted structured diets or set personal weight goals were significantly more likely to reach the 20% weight loss milestone—the threshold increasingly linked to meaningful metabolic and cardiovascular benefits.
Using advanced statistical models, the research team tracked weight loss trajectories over 12 months. They found that behavioral factors outweighed many clinical ones in predicting success. For instance, individuals who lacked self-motivation saw minimal results, even with consistent medication use. This suggests that prescribing tirzepatide without addressing psychological and behavioral readiness may limit its potential. "These findings could help physicians better counsel patients about realistic expectations and tailor their support to the needs of each patient," said Dr. Hans Johnson, research lead at Voy and lead investigator on the study.
The implications extend beyond the clinic. With obesity affecting over 40% of adults in the U.S. and rising globally, effective, personalized treatment strategies are urgently needed. The study, presented at ENDO 2026 in Chicago, suggests that pairing medication with behavioral coaching—goal setting, motivational support, structured planning—could unlock greater health gains. As more patients gain access to these drugs, the real challenge may not be the prescription itself, but how we prepare people to use it well. The future of weight management isn’t just pharmacological—it’s deeply human.